IL305727A - C5AR1 inhibitors to treat a hypersensitivity reaction to TAXANES - Google Patents

C5AR1 inhibitors to treat a hypersensitivity reaction to TAXANES

Info

Publication number
IL305727A
IL305727A IL305727A IL30572723A IL305727A IL 305727 A IL305727 A IL 305727A IL 305727 A IL305727 A IL 305727A IL 30572723 A IL30572723 A IL 30572723A IL 305727 A IL305727 A IL 305727A
Authority
IL
Israel
Prior art keywords
phenyl
c5ar1
ethyl
inhibitor
alkyl
Prior art date
Application number
IL305727A
Other languages
English (en)
Hebrew (he)
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21163292.2A external-priority patent/EP4059497A1/en
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Publication of IL305727A publication Critical patent/IL305727A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL305727A 2021-03-17 2022-03-17 C5AR1 inhibitors to treat a hypersensitivity reaction to TAXANES IL305727A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21163292.2A EP4059497A1 (en) 2021-03-17 2021-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP21217382 2021-12-23
PCT/EP2022/057007 WO2022195017A1 (en) 2021-03-17 2022-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Publications (1)

Publication Number Publication Date
IL305727A true IL305727A (en) 2023-11-01

Family

ID=81307212

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305727A IL305727A (en) 2021-03-17 2022-03-17 C5AR1 inhibitors to treat a hypersensitivity reaction to TAXANES

Country Status (11)

Country Link
US (1) US20240180888A1 (https=)
EP (1) EP4308114B1 (https=)
JP (1) JP2024512472A (https=)
BR (1) BR112023018826A2 (https=)
CA (1) CA3212816A1 (https=)
DK (1) DK4308114T3 (https=)
FI (1) FI4308114T3 (https=)
HR (1) HRP20260351T1 (https=)
IL (1) IL305727A (https=)
LT (1) LT4308114T (https=)
WO (1) WO2022195017A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025193888A1 (en) * 2024-03-14 2025-09-18 Vanqua Bio, Inc. Pyridazinone c5ar1 antagonists and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1261275A (zh) * 1997-05-27 2000-07-26 巴克·诺顿药物有限公司 给予病人口服紫杉烷类药物的方法和组合物
CA2298475A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
ES2597843T3 (es) 2005-11-24 2017-01-23 Dompé Farmaceutici S.P.A. Derivados de (R)-arilalquilamino y composiciones farmacéuticas que los contienen
EP3498269A1 (en) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

Also Published As

Publication number Publication date
US20240180888A1 (en) 2024-06-06
LT4308114T (lt) 2026-03-25
DK4308114T3 (da) 2026-03-23
FI4308114T3 (fi) 2026-03-25
BR112023018826A2 (pt) 2024-03-12
WO2022195017A1 (en) 2022-09-22
HRP20260351T1 (hr) 2026-04-24
EP4308114B1 (en) 2026-02-11
JP2024512472A (ja) 2024-03-19
CA3212816A1 (en) 2022-09-22
EP4308114A1 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
Asaki et al. Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
TWI480272B (zh) 藉由５，６－二氫－１ｈ－吡啶－２－酮與一或多種其他抗病毒化合物的組合物抑制ｃ型肝炎病毒的方法
MXPA03011448A (es) Derivados de n-arilfenilacetamida y composicion farmaceutica que los contienen.
CN1921847B (zh) 氨基醇化合物
KR20100137576A (ko) 알츠하이머병을 포함하는 타우-관련 질병의 치료에서의 에포틸론 ｄ의 용도
AU2019327262B2 (en) Pharmaceutical composition comprising antiplatelet agent and gastric acid secretion inhibitor
EP4059497A1 (en) C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP4308114B1 (en) C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
CA2828831C (en) Compounds and methods for the treatment of pain and other disorders
CN102325768B (zh) 治疗疼痛和其他疾病的化合物和方法
JP6197971B1 (ja) Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
TW201109017A (en) 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof
RU2857199C2 (ru) Предотвращение и лечение реакций гиперчувствительности к таксанам
CN117337176A (zh) 用于治疗对紫杉烷类的超敏反应的c5ar1抑制剂
JP2005511639A (ja) 虚血性疾患の治療用ドパミン再取り込み阻害活性を有するトロパン誘導体
CN115297856A (zh) 用于治疗糖尿病性视网膜病变的分拣蛋白拮抗剂
TW201712002A (zh) 第一型類升糖素肽調節子及其用途
EP4686469A1 (en) Cxcl8 inhibitors for use in the treatment of diabetes-associated comorbidities
EP3215146B1 (en) Blt2 agonists for the treatment of pain
KR20140037193A (ko) 혈청 요산을 낮추기 위한 [1,2,4]티아디아진 1,1-다이옥사이드 화합물
KR20130094811A (ko) 류코트리엔 관련 병증 치료용 페닐알킬 ｎ-히드록시우레아
EP4008325A1 (en) Cxcl8 inhibitors for use in the treatment of covid-19
Hao Discovery of Subtype Selective Agonists of the Group II Metabotropic Glutamate Receptors
IL296751A (en) cxcl8 inhibitors for use in the treatment of covid-19
JP2000351782A (ja) メタボトロピックグルタメート受容体作用薬及び新規チアゾロベンゾイミダゾール誘導体